Skip to main content
. 2021 Feb 1;8(2):ofab050. doi: 10.1093/ofid/ofab050

Table 1.

Demographics and Outcomes in Prospective COVID-19 Cohort

Group Fluvoxamine N = 65 No Therapy N = 48 P Valuea
Men 50 (59%) 35 (41%) .66
Age, years 44 ± 15 43 ± 15 .74
 Age >65 years 5 (7%) 2 (4%)
 Age 5064 years 17 (26%) 15 (31%)
Race/Ethnicity .001
 Latino 61 (94%) 34 (71%)
 White, non-Hispanic 3 (5%) 13 (27%)
 African American 1 (1.5%) 0 (0%)
 Asian 0 (0%) 1 (2%)
Chronic comorbidity 16 (25%) 18 (38%) .15
 Diabetes 11 (17%) 4 (8%)
 Hypertension, treated 11 (17%) 17 (35%)
 Lung disease 2 (3%) 1 (2%)
Days for PCR confirmation 3.7 ± 1.3 3.4 ± 1.4 .25
Disease Status at Time of Testing .064
 Asymptomatic 25 (38%) 28 (58%)
 Mild 24 (37%) 9 (19%)
 Moderateb 16 (25%) 11 (23%)
Respiratory Rate
 Day 1 17.7 ± 2.9 17.7 ± 3.4 .95
 Day 7c 12.9 ± 1.6 15.1 ± 4.1 .001
Hospitalized within 14 days 0 6 .005
 ICU care and/or Death 0 2
Symptoms at Day 14d <.001
 None 65 (100%) 19 (40%)
 13 0 (0%) 15 (31%)
 46 0 (0%) 11 (23%)
 ≥7 0 (0%) 3 (6%)

Abbreviations: COVID-19, coronavirus disease 19; ICU, intensive care unit; PCR, polymerase chain reaction.

NOTE: Values are N (%) or mean (±standard deviation).

a P values are by Fisher’s exact test for categorical variables and independent t test for continuous variables.

bThose with moderate symptoms had reduction in activities of daily living.

cSix persons hospitalized had their day 1 value carried forward.

dSymptoms assessed at day 14 included the following: persistent anxiety (n = 19); difficulty concentrating, or memory challenges, or brain fog (n = 18); fatigue (n = 16); insomnia (n = 12); persistent body aches, muscle or joint pain (n = 10); headache (n = 9); dizziness (n = 9); inability to exercise (n = 6); chills or sweats (n = 5); persistent, intermittent nonproductive cough (n = 5); episodic chest tightness; pressure, or pain (n = 3); intermittent heart palpitations or tachycardia (n = 3); shortness of breath or difficulty breathing (n = 3); diarrhea (n = 0); elevated temperature (n = 0).